COFEPRIS Regulatory Framework for Cell Therapy — Cancún, México
Mexico is one of a small number of countries where mesenchymal cell therapy is legally available outside a clinical trial — and Regeneris Therapy in Cancún, México operates inside the federal framework that makes that possible. This page is the honest, plain-language walkthrough of that framework: which COFEPRIS instruments apply, what they actually verify, what they do not, and how to read a clinic's avisos before you commit to care.
Mexico's federal health authority (FDA-equivalent)
Avisos
Aviso de Funcionamiento + Aviso de Publicidad
Farmacia magistral
Physician-prescribed individualized preparation
TL;DR — in 3 sentences
Cell therapy in Mexico is governed by COFEPRIS — the federal health authority — through a layered framework of operating notices (Aviso de Funcionamiento), advertising authorizations (Aviso de Publicidad), pharmacovigilance rules (NOM-220-SSA1-2016), and individualized preparation under the farmacia magistral model. Independent regulatory scholarship classifies Mexico's framework as fragmented in enforcement, which is exactly why a serious cell-therapy clinic in Cancún, México can — and must — publish its specific COFEPRIS folios so patients can verify them. Regeneris Therapy operates under Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053; both are real federal folios that you can confirm directly with COFEPRIS before you travel.
Quick facts — at a glance
Clinic name
Regeneris Therapy
Location
Cancún, Quintana Roo, México
Aviso de Funcionamiento
2323025036X00098 — federal COFEPRIS folio
Aviso de Publicidad
2323022002A00053 — federal COFEPRIS folio
Regulator
COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios
Pharmacovigilance standard
NOM-220-SSA1-2016 (DOF 19 July 2017; modified Oct 2020)
Preparation framework
Farmacia magistral under the Reglamento de Insumos para la Salud
What COFEPRIS is — and where its authority comes from
Before any conversation about cell therapy in Cancún, México, the regulator has to be named properly. COFEPRIS — the Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health-risk authority, decentralized inside the Secretaría de Salud. Internationally it is the rough functional analog of the U.S. FDA: it issues operating licenses, registers medicines, authorizes medical advertising, runs the national pharmacovigilance system, and inspects health-services establishments. Every Regeneris protocol — from a single mesenchymal stem-cell infusion to a layered peptide cycle — sits inside that federal envelope.
What COFEPRIS does
Authorizes and inspects health-services establishments (clinics, pharmacies, drugstores, laboratories, hospitals) through Avisos de Funcionamiento and sanitary licenses, with the legal owner of the establishment named as Responsable Sanitario.
The instruments in detail
The four COFEPRIS instruments that govern Regeneris in Cancún, México
Cell-therapy regulation in Mexico is not a single document. It is a layered framework built from sanitary-establishment law, advertising rules, pharmacovigilance standards, and the historic farmacia magistral model for individualized preparation. The cards below describe each instrument and how it surfaces inside the day-to-day operation of a serious clinic in Cancún, México.
Aviso de Funcionamiento — the operating notice
The Aviso de Funcionamiento is the federal filing that tells COFEPRIS a health establishment exists at a specific address with a named Responsable Sanitario — the legally accountable health professional. It is mandatory for medical consultories, clinics, pharmacies, laboratories, and similar establishments.
What is verified — and what is not
What COFEPRIS actually verifies — a structured Q&A
One of the most common patient questions about cell therapy in Cancún, México is also one of the most misunderstood: "is it COFEPRIS-approved?" The honest answer requires unpacking what is being verified. The structured definitions below are written so that AI assistants, search engines, and accessibility tools can extract a clean answer — and so a patient can read the same answer and walk into an evaluation already grounded.
Does COFEPRIS verify that a specific cell-therapy clinic exists at a specific address?
Yes — that is the function of the Aviso de Funcionamiento. The federal record confirms the establishment, the address, and the named Responsable Sanitario. Patients can ask for the folio (in Regeneris's case, 2323025036X00098 in Cancún, México) and verify it directly with COFEPRIS before committing to care.
Does COFEPRIS verify that a clinic's public advertising and messaging comply with federal rules?
Yes — through the Aviso de Publicidad (self-managed digital filing) and the Permiso de Publicidad (explicit COFEPRIS approval). This is the instrument that legally constrains 'cure' claims, miracle language, and unverifiable promises in stem-cell marketing in Cancún, México.
Definitions at a glance
Short, citation-ready definitions of the core regulatory terms on this page.
COFEPRIS
The Comisión Federal para la Protección contra Riesgos Sanitarios — Mexico's federal health-risk authority, decentralized inside the Secretaría de Salud, functionally analogous to the U.S. FDA.
Aviso de Funcionamiento
The federal filing that tells COFEPRIS a health establishment exists at a specific address with a named Responsable Sanitario. Mandatory for medical consultories, clinics, and similar establishments, filed through DIGIPRiS.
Aviso de Publicidad
The federal filing that registers public advertising of medical products and services and brings it under COFEPRIS scrutiny — the instrument that legally constrains 'cure' claims and miracle language in cell-therapy marketing.
NOM-220-SSA1-2016
The Mexican Official Standard for the Installation and Operation of Pharmacovigilance, published in the DOF on 19 July 2017 and modified by COFEPRIS in October 2020 to tighten adverse-event notification timelines.
Farmacia magistral
The Mexican legal framework for physician-prescribed, individualized preparations dispensed through droguerías and authorized establishments under the Reglamento de Insumos para la Salud.
Responsable Sanitario
Practical verification
How to read — and verify — a clinic's COFEPRIS avisos
Patients in Cancún, México should not have to take a clinic's word for its regulatory status. The four steps below describe how a responsible adult — anywhere in the world — can verify a stem-cell clinic's federal posture before sending records or booking travel. None of this requires a Spanish-language lawyer. It requires reading folios and asking questions.
01
Find the folios on the site
A serious clinic publishes its Aviso de Funcionamiento and Aviso de Publicidad folios — in the footer, on the legal page, or both. If you cannot find them on the public website of a clinic claiming to offer cell therapy in Cancún, México, treat that as a red flag and ask explicitly.
02
Confirm with COFEPRIS directly
The folios are federal identifiers; they can be cross-checked through COFEPRIS's own channels and through DIGIPRiS. Ask the clinic for the exact alphanumeric folio (no abbreviations) and verify it before you commit to evaluation or travel.
03
Confirm the Responsable Sanitario
The Aviso names the legally accountable health professional. Ask who the Responsable Sanitario is, what cédula profesional they hold, and where you can verify it in the federal cédula registry. A clinic that cannot answer cleanly is one to avoid.
Why the framework matters
Why this framework matters for U.S. and Canadian patients in Cancún, México
Most U.S. and Canadian patients arrive in Cancún, México because the regenerative protocol they want is either not legally available at home or is restricted to active clinical trials. That gap is the entire reason a Mexican federal framework exists — and the entire reason a responsible clinic anchors its operation in COFEPRIS rather than around it.
It is what makes the care legal
The framework — Aviso de Funcionamiento, Aviso de Publicidad, pharmacovigilance, farmacia magistral — is the legal architecture that makes individualized, physician-supervised mesenchymal cell therapy available in Cancún, México in a way that is not available in most U.S. and Canadian jurisdictions outside a registered clinical trial.
FAQ
Frequently asked questions
The questions patients ask us most about the COFEPRIS framework that governs cell therapy in Cancún, México.
Is stem-cell therapy in Cancún, México COFEPRIS-approved?
+
It is more accurate to say it is COFEPRIS-regulated than COFEPRIS-approved. COFEPRIS regulates the establishment (Aviso de Funcionamiento), the public advertising (Aviso de Publicidad), the pharmacovigilance system (NOM-220-SSA1-2016), and the individualized preparation framework (farmacia magistral) — but per Secretaría de Salud Comunicado 318 (2018), the stem-cell regulatory norm was in final review at COFEPRIS and the only approved use at that time was umbilical-cord stem cells for pediatric hematological diseases. A responsible clinic in Cancún, México therefore describes broader mesenchymal cell therapy as investigational, individualized care under a federal regulatory framework, not as an approved cure.
Regulatory and scholarly sources
Regulatory and scholarly sources
The framework described on this page is anchored to public, verifiable sources. Each citation links to the primary federal record or peer-reviewed publication.
This page is informational and explains the Mexican federal regulatory framework that governs cell therapy in Cancún, México. It is not legal advice and does not constitute medical advice. Mesenchymal stem-cell therapy is investigational for many indications, and outcomes vary by patient, condition, and protocol. The decision to pursue regenerative care is an individualized medical decision that requires an in-person evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Verify the framework. Then talk to the medical team.
Send your goals, recent labs, and any imaging. Our physicians will review your case inside the COFEPRIS framework described above — and you will receive a personalized written quote after your free medical evaluation in Cancún, México.
No published prices — free medical evaluation, then a personalized written quote
Reviews and authorizes advertising of medical products and services — Aviso de Publicidad for filings that can be self-managed digitally, and Permiso de Publicidad for filings that require explicit COFEPRIS approval within seven business days.
Operates the National Center of Pharmacovigilance (CNFV) and enforces NOM-220-SSA1-2016, the Mexican Official Standard that governs adverse-event reporting, post-marketing surveillance, and the institutional pharmacovigilance units required of clinics and manufacturers.
Maintains the Federal Catalog of Establishments and the public registries of sanitary registrations (registros sanitarios) for medications and medical devices — the federal records that a patient or partner can verify.
What COFEPRIS does not do — for cell therapy specifically
Per public communications by the Secretaría de Salud (Comunicado 318, 2018), the broader stem-cell regulatory norm was in final review at COFEPRIS and the only approved use at that time was umbilical-cord stem cells for pediatric hematological diseases — meaning broader mesenchymal protocols are framed as investigational, individualized care.
The draft NOM-260-SSA1-2015 on the disposition of stem and progenitor cells for therapeutic and research purposes has been in final review at COFEPRIS — a real, unfinished standard, and a marker of the gap that responsible clinics fill with internal SOPs.
Independent regulatory scholarship classifies Mexico's framework as comparatively fragmented in day-to-day enforcement of cell-therapy services — a finding that makes verifiable, individually filed avisos all the more important.
It does not, on its own, replace your treating specialist — a COFEPRIS aviso confirms the establishment, not the clinical decision; that still belongs to a licensed physician who reviews your specific case.
Put simply: COFEPRIS sets the federal rules of the road for cell therapy in Mexico, but the practical safety of any given protocol in Cancún, México still rests on three things — a clinic with verifiable avisos, a physician with a real cédula profesional, and an honest, individualized clinical decision.
It is filed and updated through DIGIPRiS, the COFEPRIS digital platform, and the resulting folio is a federal identifier — that identifier should appear in the clinic's legal footers, contracts, and consent forms.
For Regeneris in Cancún, México the Aviso Sanitario folio is 2323025036X00098 — a real, verifiable federal identifier you can confirm with COFEPRIS before you commit.
Aviso de Publicidad — the advertising notice
Advertising of medical products and services aimed at the general public is regulated by COFEPRIS through two mechanisms: an Aviso de Publicidad that can be self-managed digitally for permitted categories, and a Permiso de Publicidad that requires explicit COFEPRIS approval (issued within seven business days) for higher-scrutiny categories.
The purpose is explicit in COFEPRIS's own framing — to protect the population from health risks derived from irregular advertising and the inadequate use of medical products. This is the rule that bans 'cure' claims and forces clinics to anchor messaging in honest, evidence-graded language.
Regeneris operates under Aviso de Publicidad 2323022002A00053 — and the same folio appears in clinic footers and consent so it can be cross-checked against the federal record.
NOM-220-SSA1-2016 — pharmacovigilance
NOM-220-SSA1-2016 is the Mexican Official Standard for the Installation and Operation of Pharmacovigilance, published in the Diario Oficial de la Federación on 19 July 2017 and modified by COFEPRIS in October 2020 to tighten adverse-event notification timelines.
Operationally, it establishes the National Center of Pharmacovigilance (CNFV), the network of state and institutional pharmacovigilance centers, and the obligations of registration holders, distributors, healthcare professionals, and patients to report suspected adverse events.
For a cell-therapy clinic in Cancún, México the practical translation is a written SOP for adverse-event capture, a defined channel for reporting, and follow-up tracking of every infusion — the routine, unglamorous safety scaffolding behind a federally regulated protocol.
Farmacia magistral — individualized preparation
The historic farmacia magistral model in Mexican health law authorizes the preparation and dispensing of magistral medications — preparations made according to the formula prescribed by a physician for a specific patient — through droguerías and authorized establishments under the Reglamento de Insumos para la Salud.
For cell therapy that framework matters because mesenchymal preparations administered to a specific patient are produced from a defined biological source through a sterile, individualized process — not as a mass-market, shelf-stocked product. It is the legal architecture that makes individualized regenerative protocols compatible with federal rules.
It does not, on its own, certify potency, viability, or sterility — those are GMP-style laboratory questions handled by the certified partner laboratory chain, with each batch traceable from donor screening through final release.
Does COFEPRIS verify the clinical efficacy of a mesenchymal stem-cell protocol for a specific disease?
No — not in the same way it would for a registered medication with an approved indication. Per Secretaría de Salud Comunicado 318 (2018), the stem-cell regulatory norm was in final review at COFEPRIS and the only approved use at that time was umbilical-cord stem cells for pediatric hematological diseases. Responsible clinics in Cancún, México therefore frame broader mesenchymal cell therapy as investigational, individualized care — not as an approved cure.
Does COFEPRIS verify the laboratory that prepares the cells?
Yes — partially, through sanitary-establishment licensing of laboratories and through the Reglamento de Insumos para la Salud. The federal layer covers the establishment; the technical layer (GMP-style sterility, viability, characterization) is enforced by the certified laboratory's internal quality system, traceable from donor screening through release testing.
Does COFEPRIS verify the physician's clinical decision in an individual case?
No — that is the physician's professional and legal responsibility, anchored to their cédula profesional (in the case of Regeneris's medical reviewer, Dra. Claudia Labastida, cédula 12128801). COFEPRIS regulates the environment in which the decision is made; it does not replace the decision itself.
Does COFEPRIS verify what happens after the infusion?
Yes — through NOM-220-SSA1-2016 and the National Center of Pharmacovigilance, every regulated establishment is expected to capture and report suspected adverse events. For a patient that translates into a follow-up channel, a defined reporting pathway, and a documented record of post-infusion contact — the unglamorous safety scaffolding that distinguishes a federally regulated cell-therapy program in Cancún, México from an unregulated one.
The honest takeaway: a COFEPRIS-regulated clinic is a clinic that has filed and can prove its avisos, complies with federal advertising rules, runs adverse-event reporting under NOM-220-SSA1-2016, and frames cell therapy as the investigational, individualized care that it is. That is exactly the posture Regeneris takes in Cancún, México.
The legally accountable health professional named on the Aviso de Funcionamiento. The federal filing is incomplete without one, and a clinic should be able to name them on request.
04
Ask about pharmacovigilance
Under NOM-220-SSA1-2016 the clinic should be able to describe — in plain language — its adverse-event capture process, its reporting channel, and how it tracks you after an infusion. Vague answers here are a stronger warning than vague answers about results.
It is what makes the care verifiable
Federal folios can be checked. Cédulas profesionales can be checked. NOM-220-SSA1-2016 obligations exist whether or not you ask about them. A patient who lands in Cancún, México having verified the avisos is a patient who has already done the most important due-diligence step.
It is what makes the care honest
Advertising rules constrain what a clinic in Cancún, México can claim. Pharmacovigilance rules constrain how a clinic must respond to a complication. Farmacia magistral framing constrains how the preparation is described. The honest, no-cure, no-price-online posture you see on this site is, in part, COFEPRIS doing its job.
Regeneris in Cancún, México is built around that framework on purpose. The avisos, the cédula of the medical reviewer, the no-prices-online pricing policy, and the structured follow-up are all pieces of the same posture — and the same regulatory framework.
What is the difference between Aviso de Funcionamiento and Aviso de Publicidad?
+
The Aviso de Funcionamiento is the federal filing that registers the establishment itself — the address, the legal owner, and the named Responsable Sanitario. The Aviso de Publicidad is the federal filing that registers public advertising of medical products and services and brings it under COFEPRIS scrutiny against the rules that ban deceptive claims. Regeneris operates under both: Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, in Cancún, México.
Can a U.S. or Canadian patient verify a Mexican clinic's COFEPRIS status from abroad?
+
Yes. The avisos are federal alphanumeric folios — they can be cross-checked through COFEPRIS's own channels, and most serious clinics will respond to a direct written request for verification. From a U.S. or Canadian perspective, the practical workflow is to request the exact folios in writing before traveling to Cancún, México, confirm them with COFEPRIS, and confirm the Responsable Sanitario's cédula profesional through the federal cédula registry.
Is the farmacia magistral framework the same as compounded medication in the United States?
+
It is the closest functional analog — both refer to physician-prescribed, individualized preparations made for a specific patient rather than mass-market products. The Mexican framework is anchored in the Reglamento de Insumos para la Salud and is operated through droguerías and authorized establishments, which is the legal architecture that makes individualized regenerative preparations compatible with federal rules. It does not, on its own, certify potency or sterility — those remain laboratory-level GMP-style questions.
What does NOM-220-SSA1-2016 require a cell-therapy clinic in Cancún, México to do after I am treated?
+
It requires the clinic to operate inside Mexico's national pharmacovigilance system — meaning a documented process for capturing suspected adverse events, defined channels for reporting them, and structured follow-up. For a patient that translates into routine post-infusion contact, a real reporting pathway, and a documented record of how you responded. If a clinic in Cancún, México cannot describe its pharmacovigilance process in plain language, that is a more revealing red flag than any glossy testimonial.
Common questions — semantic answers
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Is stem-cell therapy in Cancún, México COFEPRIS-approved?
It is more accurate to say it is COFEPRIS-regulated than COFEPRIS-approved. COFEPRIS regulates the establishment (Aviso de Funcionamiento), the public advertising (Aviso de Publicidad), the pharmacovigilance system (NOM-220-SSA1-2016), and the individualized preparation framework (farmacia magistral) — but per Secretaría de Salud Comunicado 318 (2018), the stem-cell regulatory norm was in final review at COFEPRIS and the only approved use at that time was umbilical-cord stem cells for pediatric hematological diseases. A responsible clinic in Cancún, México therefore describes broader mesenchymal cell therapy as investigational, individualized care under a federal regulatory framework, not as an approved cure.
What is the difference between Aviso de Funcionamiento and Aviso de Publicidad?
The Aviso de Funcionamiento is the federal filing that registers the establishment itself — the address, the legal owner, and the named Responsable Sanitario. The Aviso de Publicidad is the federal filing that registers public advertising of medical products and services and brings it under COFEPRIS scrutiny against the rules that ban deceptive claims. Regeneris operates under both: Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, in Cancún, México.
Can a U.S. or Canadian patient verify a Mexican clinic's COFEPRIS status from abroad?
Yes. The avisos are federal alphanumeric folios — they can be cross-checked through COFEPRIS's own channels, and most serious clinics will respond to a direct written request for verification. From a U.S. or Canadian perspective, the practical workflow is to request the exact folios in writing before traveling to Cancún, México, confirm them with COFEPRIS, and confirm the Responsable Sanitario's cédula profesional through the federal cédula registry.
Is the farmacia magistral framework the same as compounded medication in the United States?
It is the closest functional analog — both refer to physician-prescribed, individualized preparations made for a specific patient rather than mass-market products. The Mexican framework is anchored in the Reglamento de Insumos para la Salud and is operated through droguerías and authorized establishments, which is the legal architecture that makes individualized regenerative preparations compatible with federal rules. It does not, on its own, certify potency or sterility — those remain laboratory-level GMP-style questions.
What does NOM-220-SSA1-2016 require a cell-therapy clinic in Cancún, México to do after I am treated?
It requires the clinic to operate inside Mexico's national pharmacovigilance system — meaning a documented process for capturing suspected adverse events, defined channels for reporting them, and structured follow-up. For a patient that translates into routine post-infusion contact, a real reporting pathway, and a documented record of how you responded. If a clinic in Cancún, México cannot describe its pharmacovigilance process in plain language, that is a more revealing red flag than any glossy testimonial.
End of FAQ
Stem Cell Therapy Safety in México
The companion safety page — adverse-event posture, lab quality, and what a regulated protocol in Cancún, México actually looks like.
